|
|
||||
|
SCADD Survey As most or all of you know, expanded Newborn Screening covers the fatty acid oxidation disorders (FAOD). Probably the most controversial among these is short-chain acyl-CoA dehydrogenase deficiency (SCADD) because of the uncertainty as to clinical effect. There are a number of case reports and probably many more unpublished cases in which SCADD has been identified in infants/children with problems, among which have been hypotonia, hypoglycemia, recurrent vomiting and developmental delay. On the other hand, to our knowledge there have been only two published case reports of problems in infants with SCADD who were identified by newborn screening (Koeberl DW, et al. Pediatric Research 2003; 54:1-5 and Bhala A, et al. Journal of Pediatrics 1995; 126:910-915). The question is whether SCADD is (and the extent to which it is) a source of clinical problems, i.e., whether the problems in the clinically identified cases are coincidental and not causally related to SCADD or do indeed represent disease from SCADD. To begin to get a handle on this question we’re conducting this very simple survey. We would appreciate your completing and returning it. We will compile the information and send it to the membership. |
|||